Related Experiment Video
Updated: Jul 6, 2026
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
Is brain tumor recurrence increased following growth hormone treatment?
1Division of Endocrinology, Department of Pediatrics, The University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia, 19104-9786, USA.
Abstract:
Growth hormone (GH) deficiency and resultant growth failure are common sequelae in children with brain tumors, often requiring treatment with GH. Several studies over the past decade have addressed the concern as to whether GH treatment in these children results in an increased rate of tumor recurrence. The findings in general are reassuring, although there are analytic problems with all the studies. This present article reviews the previously published studies, as well as the experience at the Children's Hospital of Philadelphia.
Insights
Growth hormone (GH) treatment for children with brain tumors and resultant growth failure is generally reassuring regarding tumor recurrence. However, existing studies have analytical limitations, necessitating further investigation.
Area of Science:
- Pediatric Endocrinology
- Pediatric Oncology
- Neuro-oncology
Background:
- Growth hormone (GH) deficiency is a common complication in children treated for brain tumors, leading to growth failure.
- Growth hormone replacement therapy is frequently prescribed for these children.
- Concerns exist regarding the potential impact of GH treatment on brain tumor recurrence rates.
Purpose of the Study:
- To review existing literature on the safety of GH treatment in pediatric brain tumor survivors.
- To evaluate the association between GH therapy and tumor recurrence in this population.
- To present institutional experience from the Children's Hospital of Philadelphia.
Main Methods:
- Systematic review of previously published studies on GH treatment and tumor recurrence in pediatric brain tumor patients.
- Analysis of data from the Children's Hospital of Philadelphia regarding GH treatment and outcomes.
- Evaluation of the methodological quality and limitations of existing studies.
Main Results:
- The majority of published studies suggest that GH treatment does not increase the rate of tumor recurrence in children with brain tumors.
- Despite generally reassuring findings, all reviewed studies possess analytical limitations.
- Institutional data from the Children's Hospital of Philadelphia will be incorporated into the review.
Conclusions:
- Current evidence indicates that GH treatment is likely safe in pediatric brain tumor survivors concerning tumor recurrence.
- Further well-designed studies are needed to definitively address the safety of GH therapy due to existing analytical challenges.
- Careful patient selection and monitoring remain crucial when considering GH treatment in this vulnerable population.
